Keeping phase III tuberculosis trials relevant: Adapting to a rapidly changing landscape-Reference-Cited by-同舟云学术

Keeping phase III tuberculosis trials relevant: Adapting to a rapidly changing landscape

Published:2019-03-22 Issue:3 Volume:16 Page:e1002767
ISSN:1549-1676
Container-title:PLOS Medicine
language:en
Short-container-title:PLoS Med

Author:

Phillips Patrick P. J.^ORCID,Mitnick Carole D.^ORCID,Neaton James D.,Nahid Payam^ORCID,Lienhardt Christian,Nunn Andrew J.^ORCID

Publisher

Public Library of Science (PLoS)

Subject

General Medicine

Reference75 articles.

1. The MRC randomized trial of streptomycin and its legacy: a view from the clinical front line;J. Crofton;J R Soc Med,2006

2. Streptomycin treatment of pulmonary tuberculosis: A Medical Research Council investigation;Br Med J,1948

3. A five-year assessment of patients in a controlled trial of streptomycin in pulmonary tuberculosis; report to the Tuberculosis Chemotherapy Trials Committee of the Medical Research Council;W Fox;Q J Med,1954

4. A Four-Month Gatifloxacin-Containing Regimen for Treating Tuberculosis;CS Merle;N Engl J Med,2014

5. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis;A Jindani;N Engl J Med,2014

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of drug-susceptible and drug-resistant tuberculosis;The Challenge of Tuberculosis in the 21st Century;2023-09-01

2. What do we talk about when we talk about “equipoise”? Stakeholder interviews assessing the use of equipoise in clinical research ethics;Trials;2023-03-18

3. Safety, effectiveness, and adherence of a short and all-oral treatment regimen for the treatment of rifampicin-resistant tuberculosis in Niger: a study protocol of a pragmatic randomised clinical trial with stratified block randomisation;Trials;2022-12-13

4. A comparison of clinical development pathways to advance tuberculosis regimen development;BMC Infectious Diseases;2022-12-09

5. Factors associated with screening failure and study withdrawal in multidrug-resistant TB;The International Journal of Tuberculosis and Lung Disease;2022-09-01